Current Studies

The facts about participating in clinical research and our ongoing studies:

First and foremost your safety is our top priority. Participating in clinical research gives you access to the latest medical and scientific innovations in medicine as well as compensates the participant(s) for time and travel. Most importantly, you are advancing medical science by contributing to the development of vital new medicines and paving the way for these new medicines to reach the market.

Please let us know if you are interested in participating in a research study. Study participants receive medical care, lab tests, and study medication at no cost, and are compensated for their participation. Transportation can be provided.

For more information, please call: 954-366-0277.




Lead Study Coordinator: Jorge Riveros
954-366-0277 x. 303 or

Lilly/LZBE: Memory Loss
A two year study to evaluate a potential disease-modifying treatment given monthly by infusion in patients 50 to 85 years old with memory loss.

Biogen/EMERGE: Alzheimer’s Disease
A two-year study to evaluate a potential disease modifying treatment given monthly by intravenous infusion on the effect of passive immunization on the progression of cognitive impairment/mild Alzheimer’s Disease in patients who are 55 to 90 years old.


Lead Study Coordinator: Adriana Bohorquez
954-366-0277 x. 302 or

Merck – APECS: Memory Loss
A two-year study with a new oral drug as a potential disease-modifying therapy in patients 50 and 85 years old who have been experiencing memory loss for a year.

Lilly/DAYBREAK: Alzheimer’s Disease
A 18 Month study to evaluate an oral potential disease modifying therapy in patients 55-85 years old with Mild Alzheimer’s Disease.

Allergan-CGP: Migraine Prevention
A five month study evaluating the effectiveness of an oral daily medication in patients 18 to 75 who suffer from migraine headaches with or without aura.

Allergan-UBR: Migraine
Acute treatment- a single attack study to evaluate the effectiveness of an oral abortive medication for migraine with or without aura. Participants must be 18-75 years of age with 2-8 migraines per month. (Optional 12-month open label extension)


Lead Study Coordinator: Rebecca Nembhard
954-366-0277 x. 301 or

Colucid 302/SPARTAN: Migraine
Acute treatment- a study to evaluate a Novel oral abortive migraine medication (with optional 12 month open label extension).



Lead Study Coordinator: Lucy Vargas
954-981-4491 or

Pearl Therapeutics – COPD: Moderate to Severe COPD
One-year study to evaluate combination therapy of two or three FDA approved medications for the treatment of moderate or severe COPD, Participants must be 40-80 years of age with documented history of exacerbations.



Lead Study Coordinator: Michelle Kroll Fistel, LPN, CCRC
954-475-8171 x.134 or 

Biogen 109MS414 MITIGATE: Multiple Sclerosis
An 18-week long study to evaluate whether montelukast can reduce the severity of GI events in subjects with relapsing forms of Multiple Sclerosis taking TECFIDERA®

MedDay: Multiple Sclerosis
A 15-month study followed by a 12-month extension for patients with Progressive MS (Primary or Secondary), must be 18-65 years of age.

Novartis-COMB: Multiple Sclerosis
A 2-year study for Multiple Sclerosis to evaluate an investigational monthly IV medication vs. Teriflunomide. Participants must be 18-55 years of age, with Relapsing Remitting or Secondary progressive MS.

Mallinckrodt: Multiple Sclerosis
Observational study using H.P. Acthar Gel to treat patients with multiple sclerosis experiencing exacerbations

Novartis – ASSESS: Relapsing-Remitting MS
A one-year study to compare efficacy and safety of 2 doses of oral Fingoli mod (Gilenya) to Copaxone in adults at least 18 years old with relapsing remitting multiple sclerosis.

Sanofi IVSS: OBS14379
A prospective observational cohort study in adult patients with relapsing multiple sclerosis to assess patient safety during and after LEMTRADA® (alemtuzumab) infusions of the first treatment course

Sun Pharma – SPASTICITY: Spasticity Due to MS
A 22-week study evaluating a new formulation of extended release baclofen in patients 18 years old and older with spasticity due to multiple sclerosis.

Sun Pharma – SPASTICITY OL: Spasticity Due to MS
A long-term safety study evaluating a new formulation of extended release baclofen in patients 18 years old and older with spasticity due to MS, who completed 26 weeks of treatment in the spasticity trial.


Lead Study Coordinator: Dalia Ramos, RMA, CCRP
954-475-8171 x.132 or

BAN2401-G000-201: Alzheimer’s Disease
A placebo-controlled, double-blind, parallel-group, Bayesian Adaptive Randomization Design and Dose Regimen-finding study to evaluate safety, tolerability and efficacy of BAN2401 in subjects with early Alzheimer’s disease.

Eli Lilly – AMARANTH: Early Alzheimer’s Disease (MMSE 21-30)
A 24-month long study to evaluate a potential disease modifying therapy, oral formulation, in patients between 55 and 85 years old with early Alzheimer’s disease.

Neurim Pharmaceuticals Ltd. – reCOGNITION Mild Alzheimer’s disease (MMSE 21-26)
This study is a Phase 2, randomized, placebo controlled, dose ranging study of piromelatine (5, 20, and 50 mg daily for 6 months) versus placebo to determine an effective dose based on efficacy (cognitive performance), safety and tolerability in patients with mild dementia due to AD.

Suven Life Sciences Ltd: Moderate Alzheimer’s disease (MMSE 12-20)
26-week long study to evaluate the safety and efficacy of SUVN-502 with donepezil and memantine for the treatment of moderate Alzheimer’s disease.

TransTech Pharma: Mild Alzheimer’s Disease (STEADFAST) (MMSE 21-26)
An 18-month long study testing the efficacy and safety of an investigational medication on improving memory in patients with mild Alzheimer’s disease, age 50 and over, currently taking AChEI (donepezil, rivastigmine, galantamine) or memantine.


Lead Study Coordinator: Fanny Gully, CRC
954-475-8171 x.146 or 

Pfizer TANGO: Chronic Low Back Pain
56-week long, randomized, double-blind, placebo and active controlled study of the analgesic efficacy and safety of Tanezumab in subjects with chronic low back pain

Seratrials – 05035
One time blood draw for patients with multiple sclerosis – Amex gift card to those that qualify. There are a few projects: (1) MS with EDSS 1.5 or less (2) MS with EDSS 3.0 or more (3) RRMS currently taking Copaxone


Lead Study Coordinator: Magdeli Ramos, CCRC
954-475-8171 x.138 or 

Alder Biopharmaceuticals: Migraine Prevention
Study to assess ALD403 in the prevention of migraine headache in frequent episodic migraineurs.

Allergan-CGP: Migraine Prevention
A five month study evaluating the effectiveness of an oral daily medication in patients 18 to 75 who suffer from migraine headaches with or without aura.